Development of a next-generation immunoprevention platform against HIV-1
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93024C00050
- Awardee
-
Neovaxsyn Inc. UEI EHMTBALCKFE8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · SBIRPHS20241 · Posted Jul 7, 2023
- Contract value 100% obligated
- $300,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Ames, IA 50011, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $300,000 |
About this award
This federal contract award to Neovaxsyn Inc., a minority-owned small disadvantaged business, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The $300,000 firm fixed-price contract supports the development of a next-generation immunoprevention platform against HIV-1, with a final completion date of October 31, 2025.
The contract was awarded under the Small Business Innovation Research (SBIR) program, which is a set-aside for small businesses. Neovaxsyn has previously received multiple SBIR contracts and grants from NIAID and the National Institute of Mental Health, focused on innovative approaches to developing HIV vaccines, including the use of nanoparticle technologies and novel immunogen strategies. This specific contract builds on Neovaxsyn's expertise in biotechnology research and development to advance HIV prevention capabilities.
Quick answers
Who was awarded contract 75N93024C00050?
75N93024C00050 was awarded to Neovaxsyn Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2024.
How much is contract 75N93024C00050 worth?
The government has obligated $300,000 on 75N93024C00050.
Was contract 75N93024C00050 competed?
The extent of competition for 75N93024C00050 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award